First cefixime of modern pharmaceutical passed the consistency evaluation

Today, Hyundai pharmaceutical announced that it has recently received the approval document for supplementary application of cefixime granules (50mg) approved and issued by the State Drug Administration, approving the drug to pass the quality and efficacy consistency evaluation of generic drugs Cefixime is the first third generation oral cephalosporin, which is clinically suitable for Streptococcus sensitive to cefixime (except Enterococcus), bacterial infectious diseases caused by pneumococcus, Neisseria gonorrhoeae, hansococcus catarrhalis, Escherichia coli, Klebsiella, Serratia, Proteus and influenza bacteria, including bronchitis, bronchiectasis (at the time of infection), secondary infection of chronic respiratory system infection, pneumonia, cholecystitis, cholangitis, scarlet fever, etc The original manufacturer of cefixime is Fujisawa Pharmaceutical Co., Ltd of Japan The product dosage forms include capsule (cefspan Ⓡ capsules 50mg and 100mg) and fine-grained agent (cefspan Ⓡ fine granules 50mg) According to CDE website, no cefixime granules (50mg) from other companies have passed the consistency evaluation Baiyunshan Pharmaceutical General Factory of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd and Chengdu Beite Pharmaceutical Co., Ltd have applied for conformity evaluation of the above specifications of drugs Up to now, the cumulative input cost of Guoyao Zhijun for the consistency evaluation of cefixime granules (50mg) is about 22 million yuan (Unaudited) Adorable adorable